Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Description

In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.

Conditions

Atrial Fibrillation

Talk to us

Study Overview

On this page

Study Details

Study overview

In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.

A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Condition
Atrial Fibrillation
Intervention / Treatment

-

Contacts and Locations

Chicago

Jesse Brown VA Medical Center, Chicago, Illinois, United States, 60612

Chicago

Rush University Medical Center, Chicago, Illinois, United States, 60612

Chicago

University of Illinois at Chicago, Chicago, Illinois, United States, 60612

Oak Lawn

Advocate Christ Medical Center, Oak Lawn, Illinois, United States, 60453

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥ 18 years of age
  • * History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF
  • * ECG that was recorded within 1 month of randomization showing AF
  • * Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD
  • * Able to give informed consent
  • * Permanent AF or isolated atrial flutter
  • * Cardiac or thoracic surgery within the previous 6 months
  • * Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital)
  • * Medical condition that is likely to be fatal in less than one year
  • * A history of prior AF ablation
  • * Have already been tried on 2 or more AADs in the past for AF
  • * Creatinine clearance \<40 ml/min
  • * Left ventricular ejection fraction \< 50%
  • * Contra-indication to a Class I AAD e.g., structural heart disease, or history of MI
  • * Contra-indication to a Class III AAD, e.g., congenital or acquired long QT syndrome with QTc\>480 ms in females and \>460 ms in males at baseline
  • * A reversible cause of AF (e.g., hyperthyroidism)
  • * Females who are pregnant or nursing
  • * History of severe AV node dysfunction unless an electronic pacemaker is present
  • * First- or second-degree relative has already participated in the study
  • * Unable to adhere to study procedures that are strictly for research purposes

Ages Eligible for Study

18 Years to 100 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Illinois at Chicago,

Study Record Dates

2025-06-30